Growth Hormone Supplementation May Not Improve Live Birth Rate in Poor Responders

Jinliang Zhu 1,2†, Ying Wang 1,2†, Lixue Chen 1,2, Ping Liu 1,2, Rong Li 1,2 and Jie Qiao 1,2*

1 Department of Obstetrics and Gynecology, Center for Reproductive Medicine, Peking University Third Hospital, Beijing, China, 2 National Clinical Research Center for Obstetrics and Gynecology, Beijing, China

Backgrounds: Growth hormone (GH) was used for many years to increase ovarian response in poor ovarian responders (PORs). Although meta-analysis suggested that GH therapy improve early clinical outcomes, the benefit of GH usage on chance of live birth was still widely debated. This study was to determine whether or not GH supplementation influences the live birth rate (LBR).

Methods: A total of 3,080 expected PORs receiving and not receiving (control) GH adjuvant therapy at Peking University Third Hospital from January 2017 to March 2018 were retrospectively analyzed. The basal characteristics of patients were compared using analysis of variance (continuous variables) and categorical variables were evaluated with a chi-square test. Logistic regression analyses were used to evaluate potential associations of LBR with GH treatment while adjusting other confounding factors.

Results: No statistically significant differences existed in miscarriage rate (5.3 vs. 12.5%; \( p = 0.076 \)) and LBR (37.7 vs. 34.5%; \( p = 0.426 \)) in young expected PORs (<35 years of age). Moreover, no significant differences existed in the miscarriage rate (25.6 vs. 23.3%; \( p = 0.681 \)) and LBR (17.8 vs. 17.9%; \( p = 0.977 \)) in the old expected PORs (≥35 years of age). Logistic regression suggested that GH adjuvant therapy did not improve the LBR in young (OR, 1.27; 95% CI, 0.88–1.85; \( p = 0.203 \)) and elderly expected PORs (OR, 1.20; 95% CI, 0.82–1.76; \( p = 0.342 \)), while GH was not associated with risk of miscarriage in young (OR, 0.37; 95% CI, 0.11–1.24; \( p = 0.108 \)) and elderly expected PORs (OR, 0.91; 95% CI, 0.43–1.93; \( p = 0.813 \)). In subgroup analysis, GH treatment significantly increased the day 3 embryos available rate in the subgroup of young PORs with the long down-regulation (63.11 vs. 49.35%; \( p = 0.004 \)), while significantly reduced the risk of miscarriage in the subgroup of young PORs with GnRH antagonist protocol (0.00 vs. 12.6%; \( p = 0.023 \)). There was no significant difference for LBR in PORs with GnRH antagonist (<35 years [35.19 vs. 28.45%; \( p = 0.183 \)]; ≥35 years [12.96 vs. 14.03%; \( p = 0.707 \)]), GnRH-a long (<35 years [33.33 vs. 36.99%; \( p = 0.597 \)]; ≥35 years [17.44 vs. 20.28%; \( p = 0.574 \)]) and long down-regulation (<35 years [58.82 vs. 41.90%; \( p = 0.193 \)]; ≥35 years [43.33 vs. 25.30%; \( p = 0.065 \)]).

Conclusions: Growth hormone treatment may not improve live birth rate in expected poor responders.

Keywords: poor ovarian responder, growth hormone, live birth rate, ovarian stimulation protocol, in vitro fertilization
INTRODUCTION

Controlled ovarian hyperstimulation (COH) was used to achieve multi-follicular development. A poor response to ovarian stimulation is estimated to occur in 5.6–35.1% of patients (1–6), depending on the definition of poor ovarian responder (POR). A poor response to ovarian stimulation is not common, and presents a significant therapeutic challenge. Many approaches have been proposed to improve clinical outcomes of PORs, including a modified ovarian stimulation protocol (7, 8), androgen treatment (9, 10), and a stem cell ovarian transplant (11).

The reasonable use of growth hormone (GH) in PORs is based on the requirement for follicular growth in animal studies (12, 13). Then, GH was reported to increase the density of granulosa follicle-stimulating hormone (FSH) and luteinizing hormone receptors in older PORs (14) and enhance oocyte mitochondrial activity in older women (15). GH has been used for many years to increase the ovarian response in clinical practice (16, 17). A number of studies have suggested that GH adjuvant therapy increases the number of retrieved oocytes, mature oocytes, and good quality embryos in POR cohorts (18–23). Moreover, a systematic review, including randomized controlled trials and single center retrospective studies, suggested that the addition of GH in ovarian stimulation increased the probability of clinical pregnancies and live births in PORs (24–26). However, a recent updated meta-analysis, including the largest multicentered randomized controlled trial (RCT) conducted by the LIGH investigators failed to find a significant difference in the live birth rate (LBR) after GH adjuvant therapy in PORs (27).

The discrepant finding may be related to the lack of a clear definition of POR and participation heterogeneity. A systematic review of 47 RCTs used 41 different definitions of a POR (28). To standardize the POR, the POSEIDON group proposed a more detailed definition of a POR (29), compared to the “Bologna criteria.” The POSEIDON group divided patients into unexpected and expected PORs based on the antral follicle count (AFC) and/or the anti-Mullerian hormone (AMH) level. As underlying etiologies of PORs were different in young and old sub-PORs, it is important that maternal age be taken into consideration in the POSEIDON classification. In view of the advantages of the POSEIDON classification, we set out to investigate the efficacy of GH adjuvant therapy in expected PORs based on POSEIDON classification. We hypothesized that GH treatment might benefit for sub-PORs in terms of increased LBR based on POSEIDON.

METHODS

Participants

A total of 3,080 expected PORs undergoing the first fresh in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) cycles from January 2017 to June 2018 at Peking University Third Hospital were included. The inclusion criterion were based on the definition of expected PORs released by POSEIDON in 2016 (29), as follows: POSEIDON group 3 (PG3) includes patients <35 years of age with poor pre-stimulation ovarian reserve parameters (AFC < 5 and/or AMH < 1.2 ng/mL); and POSEIDON group 4 (PG4) includes patients ≥35 years of age with poor pre-stimulation ovarian reserve parameters (AFC < 5 and/or AMH < 1.2 ng/mL). The exclusion criteria were as follows: (1) azoospermia or severe oligospermia; and (2) abnormal karyotyping. In the PG3 group, 271 and 1021 women received or did not (control) receive GH adjuvant therapy, respectively. In the PG4 group, 557 and 1,231 women received and did not receive (control) GH adjuvant therapy, respectively.

Protocols

COH was achieved in those patients by using either recombinant FSH (rFSH) or human menopausal gonadotropin (HMG) in various flexible protocols. Each COH protocol with and without GH was used in our center based on physician experience. In the long gonadotrophin-releasing hormone agonist (GnRH-a) protocol, patients were administered a 0.1 mg triptorelin daily injection for 14 days or a single 1.3/1.8 mg triptorelin injection during the midterm luteal phase of the previous menstrual period followed by recombinant FSH (Gonal-f; Merck Serono, Geneva, Switzerland and Purigen, Organon, P.O. Box 20 OssN3404BH, Netherlands) or hMG (Livzon Pharmaceutical Group, Zhuhai, China). In the long down-regulation (LDR), patients underwent pituitary down-regulation by 3.75 mg of triptorelin acetate or leuprolrelin acetate on the first day of the cycle followed by rFSH or HMG 28–35 days later. In the flare cycle, patient received GnRH-a from day 2nd of the menstrual cycle onward then rFSH or HMG were given in the 3rd day. In the antagonist protocol, patients started with rFSH treatment on the 2nd day of the cycle by once-daily injection. Follicle development was monitored by ultrasound. After 5 days of this treatment, the antagonist (cetrorelix acetate or ganirelix acetate) was administered daily. The rFSH dose was adjusted according to individual ovarian response, which was assessed by daily ultrasound examination. The antagonist continued up to and including human chorionic gonadotropin (hCG) day. In all treatment protocols, when at least 2 leading follicles reached 18 mm in size, ovulation was induced by administering 250 µg of r-hCG (MerckSerono S.p.A), and ovum collection was performed between 34 and 38 h later. Progesterone gel (90 mg) was inserted into the vagina daily for 14, 21, and 30 days after fresh embryo transfer. Patients in the GH group received 4 IU/d of GH (Saizen; Merck Serono, Geneva, Switzerland), beginning on the initial day of gonadotrophin until the day of hCG injection. Criteria for treating PORs with GH was mainly based on physician experience, and affordability was one of factors in assigning GH treatment to PORs.

Outcomes Measured

The main outcomes of the study were as follows: number of oocytes collected; day 3 embryos available rate; implantation rate (IR); clinical pregnancy rate (CPR) per transfer cycle; miscarriage rate (MR); and LBR per transfer cycle. An embryo was defined as an available day 3 embryo if the embryo had ≥5 cells and contained <20% anucleated fragments. The IR was calculated as the ratio of the number of gestational sacs to the number of embryos transferred. Clinical pregnancy was diagnosed when a
gestational sac was detected by transvaginal ultrasound scan 4 weeks after embryo transfer. Live birth was defined as the birth in which at least one fetus was live born after 28 weeks gestation.

### Statistical Analysis
All statistical analyses were performed with the Statistical Package for the Social Sciences software (SPSS, version 17.0; SPSS, Inc., Chicago, IL, USA). The basal characteristics of patients were compared using analysis of variance (continuous variables) and categorical variables were evaluated with a chi-square test. Logistic regression analyses were used to evaluate potential associations of LBR and miscarriage rate with GH treatment while adjusting other confounding factors, including maternal age/body mass index (BMI), infertility duration, the type of infertility, female parity, main infertility causes, AMH, AFC, ovarian stimulation protocol, the number of collected oocytes, the number of transferred embryos, and transfer stage (day 3 vs. day 5). All tests were two-sided, a $P < 0.05$ was considered to be statistically significant.

### Ethical Approval
This retrospective cohort study was approved by the Ethics Committee of Reproductive Medicine, Peking University Third Hospital on 16 AUG 2019, the reference number was 2019SZ-062.

### RESULTS
A total of 3080 women were recruited to the study. Eight hundred twenty-eight women underwent IVF/ICSI fresh cycles with GH co-treatment; 2252 women who did not receive GH co-treatment comprised the control group. There was no significant difference in the LBR between the two groups (25.05 vs. 25.93%; $P = 0.698$). Moreover, the LBR was similar between the GH and control groups with single embryo transfer stratified by days 3 and 5 transfers (D3, 15.84 vs. 12.23%; $p = 0.373$ and D5, 10.71 vs. 16.83%; $p = 0.562$). The trend was the same in double embryo transfers (Table 1). Consequently, we divided the patients into PG3 and PG4 for comparison.

### Clinical Outcomes in the PG 3
A total of 1,292 women were recruited to the PG3 group. In this group, 271 women were assigned to the GH adjuvant therapy group and 1,021 women were assigned to the control group. The baseline characteristics of patients and ovarian stimulation are shown in Table 2. There was no statistically significant difference in the baseline characteristics of patients and ovarian stimulation between GH treatment and control groups, except for duration of infertility (3.67 ± 2.52 vs. 3.29 ± 2.48; $p = 0.030$) and the protocol used for ovarian stimulation ($p < 0.001$). The number of cycles canceled before oocyte retrieval (2.58 vs. 2.15%; $p = 0.672$) was not significantly different between the two groups.

The clinical outcomes are depicted in Table 3. No statistically significant differences were found in the day 3 embryo available rate (52.31 vs. 54.70%; $p = 0.131$), the number of transferred embryos (1.66 ± 0.61 vs. 1.69 ± 0.60; $p = 0.445$), cycles reaching embryo transfer [ET] (71.97 vs. 71.17%; $p = 0.866$), proportion of day 3 ET (94.21 vs. 94.51%; $p = 0.871$), IR (28.82 vs. 28.99%; $p = 0.953$), MR(5.33 vs. 12.54%; $p = 0.076$), CPR (40.98 vs. 41.65%; $p = 0.870$), and LBR (37.70 vs. 34.54%; $p = 0.426$) between the two groups. In subgroup analysis, the LBR was similar between the GH and control groups with single embryo transfer stratified by days 3 and 5 transfers (D3, 30.00 vs. 18.99%; $p = 0.215$ and D5, 10.00 vs. 15.38%; $p = 1.000$). The trend was the same in double embryo transfers. We conducted logistic regression to adjust bias between the two groups. GH adjuvant therapy may not improve the LBR in young expected PORs (OR, 1.27; 95% CI, 0.88–1.85; $p = 0.203$; Table 4), while GH may not reduce the miscarriage rate in young expected PORs (OR, 0.37; 95% CI, 0.11–1.24; $p = 0.108$; Table 5).

### Clinical Outcomes in PG 4
A total of 1,788 women were recruited to the PG4 group. In this group, 557 and 1,231 women were assigned to the GH adjuvant therapy and control groups, respectively. As shown in Table 2, there was no statistically significant difference in the baseline characteristics of patients and ovarian stimulation between GH treatment and control groups, except the protocol used for ovarian stimulation ($p < 0.001$) and dose of gonadotrophin (3,401 ± 1,382 IU vs. 3,577 ± 1,280 IU; $p = 0.009$).

The clinical outcomes are shown in Table 3. Similar to the PG3 group, no statistically significant differences were found in the day 3 embryo available rate (50.55 vs. 51.02%; $p = 0.721$) the number of transferred embryos (1.54 ± 0.70 vs. 1.59 ± 0.64; $p = 0.221$), cycles reaching ET (63.93 vs. 65.32%; $p = 0.574$), proportion of day 3 ET (94.74 vs. 92.03%; $p = 0.105$), IR (15.13 vs. 16.52%; $p = 0.442$), CPR (24.38 vs. 25.61%; $p = 0.671$), MR (25.64 vs. 23.28%; $p = 0.681$), and LBR (17.81 vs. 17.89%; $p = 0.977$) between the two groups. In subgroup analysis, the LBR was similar between the GH and control groups with single embryo transfer stratified by days 3 and 5 transfers (D3, 9.86 vs. 8.67%; $p = 0.773$ and D5, 11.11 vs. 17.74%; $p = 0.722$). The trend was the same in double embryo transfers. Logistic regression indicated that GH adjuvant therapy may not improve the LBR in old expected PORs (OR, 1.20; 95% CI, 0.82–1.76; $p = 0.342$; Table 4), while GH may not reduce the miscarriage rate in old expected PORs (OR, 0.91; 95% CI, 0.43–1.93; $p = 0.813$; Table 5).

### Table 1 Live birth rate in single and double embryo transfer stratified by days 3 and 5 transfers.

| Live birth rate | All | GH | CN | $P$-value |
|----------------|-----|----|----|-----------|
| Day 3 ET       | 122/503 (24.25%) | 353/1,388 (25.43%) | 0.602 |
| SET            | 16/101 (15.84%) | 28/229 (12.23%) | 0.373 |
| DET            | 106/402 (26.37%) | 325/1,159 (28.04%) | 0.518 |
| Day 5 ET       | 4/29 (13.79%) | 17/101 (16.83%) | 1.000 |
| SET            | 3/28 (10.71%) | 17/101 (16.83%) | 0.562 |
| DET            | 1/1 (100%) | — | — |
TABLE 2 | Basal characteristics of patients and ovarian stimulation.

|                          | Treatment cycles | Maternal age <35 years | Maternal age ≥35 years |
|--------------------------|------------------|------------------------|------------------------|
|                          | GH               | CN                     | GH                     | CN                     |
| Maternal BMI (kg/m2)     | 22.86 ± 3.55     | 22.46 ± 3.63           | 23.00 ± 3.04           | 23.28 ± 3.60           |
| Infertility duration (yrs)| 3.67 ± 2.52      | 3.29 ± 2.48            | 4.77 ± 6.68            | 4.71 ± 4.60            |
| Paternal age (yrs)       | 31.89 ± 3.41     | 32.17 ± 3.89           | 40.65 ± 5.38           | 40.55 ± 5.84           |
| Primary infertility (%)  | 168 (61.99%)     | 627 (61.41%)           | 181 (32.50%)           | 416 (33.79%)           |
| Nulliparous (%)          | 266 (98.15%)     | 981 (96.08%)           | 435 (78.10%)           | 975 (79.20%)           |
| Main infertility cause (%)| 0.069            | 0.086                  | 0.098                  | 0.595                  |
| Basal characteristics    |                  |                        |                        |
| FSH (mIU/ml)             | 8.25 ± 4.34      | 7.64 ± 4.30            | 8.17 ± 3.78            | 8.27 ± 4.16            |
| E2 (pmol/L)              | 208.99 ± 302.28  | 202.16 ± 213.19        | 228.30 ± 429.62        | 205.66 ± 207.65        |
| LH (mIU/ml)              | 3.32 ± 2.23      | 3.46 ± 2.37            | 3.79 ± 3.02            | 3.68 ± 2.57            |
| AMH (ng/ml)              | 0.96 ± 1.43      | 1.10 ± 1.27            | 0.76 ± 0.62            | 0.82 ± 0.74            |
| AFC (%)                  | 17 (6.27%)       | 101 (9.89%)            | 27 (4.85%)             | 75 (6.09%)             |
| Basal hormone            |                  |                        |                        |
| Male                     | 178 (65.68%)     | 604 (59.16%)           | 374 (67.15%)           | 818 (66.45%)           |
| Female                   | 55 (21.99%)      | 247 (24.19%)           | 122 (21.90%)           | 277 (22.50%)           |
| Mixed                    | 65 (25.00%)      | 247 (24.19%)           | 122 (21.90%)           | 277 (22.50%)           |
| Protocol (%)             | 0.62             | 0.68                   | 0.59                   | 0.59                   |
| LDR                      | 23 (8.49%)       | 144 (14.10%)           | 64 (11.49%)            | 105 (8.53%)            |
| GnRH agonist long protocol | 82 (30.26%)    | 328 (32.13%)           | 124 (22.26%)           | 311 (25.26%)           |
| GnRH antagonist protocol | 132 (48.71%)    | 472 (46.23%)           | 293 (52.60%)           | 664 (53.94%)           |
| Micro stimulate protocol | 24 (8.86%)      | 32 (3.13%)             | 75 (13.46%)            | 90 (7.31%)             |
| Natural cycle            | 0 (0.00%)        | 19 (1.86%)             | 0 (0.00%)              | 19 (1.54%)             |
| Total doses of gonadotropin (IU) | 3,535 ± 1,289 | 3,492 ± 1,269         | 3,401 ± 1,382          | 3,577 ± 1,280          |
| Endometrial thickness (mm) | 10.57 ± 2.19   | 10.71 ± 1.79           | 10.07 ± 1.98           | 10.10 ± 2.00           |

GH, growth hormone; CN, control; BMI, body mass index; FSH, follicle-stimulating hormone; LH, luteinizing hormone; E2, estradiol; AMH, Anti-Müllerian hormone; AFC, Antral follicle count; LDR, Long down-regulation.

Subgroup Analysis in PG3 and PG4

The participants were stratified into three subgroups based on the ovarian stimulation protocol. The baseline characteristics of patients in the subgroups that underwent the LDR, GnRH-a long and antagonist protocols are shown in Supplementary Tables 1–3. As shown in Supplementary Tables 1, 2, there were no significant differences in the number of oocytes collected between GH treatment and control. The day 3 embryo available rate after GH treatment in young PORs who underwent LDR was significantly higher than the control group (63.11 vs. 49.35%; p = 0.004). As shown in Supplementary Table 3, the number of oocytes collected following GH treatment was significantly lower than the control group in subgroup that underwent the antagonist protocol (<35 years [5.92 ± 4.35 vs. 7.04 ± 4.83; p = 0.019]); however, the day 3 embryo available rate was not significantly different between the two groups in the subgroup that underwent the antagonist protocol (53.43 vs. 57.32; p = 0.101). Finally, LBR was comparable between GH treatment and control in GnRH antagonist (<35 years [35.19 vs. 28.45%; p = 0.183]; ≥35 years [12.96 vs. 14.03%; p = 0.707]), GnRH-a long protocol (<35 years [33.33 vs. 36.99%; p = 0.597]; ≥35 years [17.44 vs. 20.28%; p = 0.574]) and LDR (<35 years [58.82 vs. 41.90%; p = 0.193]; ≥35 years [43.33 vs. 25.30%; p = 0.065]; Table 6).

DISCUSSIONS

Main Findings

This study demonstrated that GH adjuvant therapy may not increase the chance of achieving live birth in expected PORs, when adjusted for confounding factors and conducting a sub-analysis with embryo transfer number (single vs. double)
### TABLE 3 | Clinical outcomes.

|                  | Maternal age <35 |         |         | Maternal age ≥35 |         |         |
|------------------|------------------|---------|---------|------------------|---------|---------|
|                  | GH               | CN      | P-value | GH               | CN      | P-value |
| No. of oocyte retrieval cycles (%) | 264              | 999     | –       | 535              | 1,191   | –       |
| No. of oocytes collected | 6.56 ± 4.69      | 7.66 ± 5.09 | 0.001   | 5.55 ± 3.93      | 5.40 ± 4.43 | 0.513   |
| No. of cleavage oocytes | 1,212            | 5,395   | –       | 2,095            | 4,612   | –       |
| Day 3 embryo available rate | 634 (52.31%)    | 2,951 (54.70%) | 0.131   | 1,059 (50.55%)  | 2,353 (51.02%) | 0.721   |
| Cycles reaching ET/OR (%) | 190 (71.97%)  | 711 (71.17%) | 0.866   | 342 (63.93%)  | 778 (65.32%) | 0.574   |
| Day 3 ET | 179 (94.21%) | 672 (94.51%) | 0.871   | 324 (94.74%) | 716 (92.03%) | 0.106   |
| Day 5 ET | 11 (5.79%)  | 39 (5.49%)  | –       | 18 (5.26%)   | 62 (7.97%)  | –       |
| No. of transferred embryo | 1.66 ± 0.61      | 1.69 ± 0.60 | 0.445   | 1.54 ± 0.70     | 1.59 ± 0.84 | 0.221   |
| Clinical pregnancy rate/ET (%) | 75 (40.98%) | 287 (41.65%) | 0.824   | 78 (24.38%) | 189 (25.61%) | 0.591   |
| Total No. of transplant embryos | 340              | 1,304   | –       | 595             | 1,344   | –       |
| Implantation rate/ET (%) | 98 (28.82%) | 378 (28.99%) | 0.953   | 90 (15.13%) | 222 (16.52%) | 0.442   |
| Miscarriage rate/CP (%) | 4 (5.33%)  | 36 (12.54%) | 0.076   | 20 (25.64%) | 44 (23.28%) | 0.681   |
| Live birth rate/ET (%) | 69 (37.70%) | 238 (34.54%) | 0.426   | 57 (17.81%) | 132 (17.89%) | 0.977   |
| Day 3 ET | 67 (34.73%) | 232 (34.52%) | 0.469   | 55 (16.98%) | 121 (16.90%) | 0.976   |
| SET | 9/30 (30.00%) | 15/79 (18.99%) | 0.215   | 7/71 (9.86%) | 13/150 (8.67%) | 0.773   |
| DET | 58/149 (38.93%) | 217/593 (36.59%) | 0.598   | 48/253 (18.97%) | 108/566 (19.08%) | 0.971   |
| Day 5 ET | 2 (18.18%) | 6 (15.38%)  | 1.000   | 2 (11.11%)  | 11 (17.74%) | 0.364   |
| SET | 1/10 (10.00%) | 6/39 (15.38%) | 1.000   | 2/18 (11.11%) | 11/62 (17.74%) | 0.722   |
| DET | 1/1 (100%) | –         | –       | –              | –       | –       |

GH, growth hormone; CN, control; OR, oocyte retrieved; ET, embryo transfer; CP, clinical pregnancy; SET, single embryo transfer; DET, double embryo transfer.

### TABLE 4 | Logistic regression for live births, while adjusting for confounders.

|                  | Maternal age <35 |         |         | Maternal age ≥35 |         |         |
|------------------|------------------|---------|---------|------------------|---------|---------|
|                  | GH               | OR 95%CI | P-value | GH               | OR 95%CI | P-value |
| GH               | 0.203            | 1.27 (0.88–1.85) | 0.342   | 1.20 (0.82–1.76) |
| Maternal age     | 0.548            | 1.02 (0.96–1.08) | 0.001   | 0.76 (0.71–0.82) |
| Maternal BMI     | 0.267            | 0.98 (0.93–1.02) | 0.777   | 1.01 (0.96–1.06) |
| Infertility duration | 0.627          | 0.98 (0.92–1.05) | 0.468   | 0.98 (0.94–1.03) |
| Primary infertility | 0.162          | 0.80 (0.58–1.10) | 0.295   | 0.81 (0.55–1.20) |
| Nulliparous      | 0.396            | 0.69 (0.29–1.63) | 0.592   | 0.87 (0.51–1.47) |
| Main infertility cause |               |         |         |                  |         |         |
| Male             | 0.321            | –       | –       | 0.121            | –       | –       |
| Female           | 0.817            | 0.94 (0.56–1.58) | 0.319   | 0.72 (0.38–1.37) |
| Mixed            | 0.386            | 1.29 (0.73–2.28) | 0.164   | 0.61 (0.30–1.23) |
| Unexplained      | 0.487            | 1.30 (0.62–2.76) | 0.468   | 0.98 (0.57–3.35) |
| AMH              | 0.453            | 0.94 (0.81–1.10) | 0.591   | 0.93 (0.70–1.23) |
| AFC              | 0.129            | 0.96 (0.92–1.01) | 0.703   | 1.01 (0.96–1.07) |
| Protocol         |                  |         |         |                  |         |         |
| GnRH agonist long protocol | 0.242   | –       | –       | 0.331            | –       | –       |
| LDR              | 0.207            | 1.35 (0.85–2.15) | 0.248   | 1.38 (0.80–2.40) |
| GnRH antagonist   | 0.19             | 0.79 (0.56–1.12) | 0.266   | 0.79 (0.53–1.19) |
| Flare cycle      | 0.631            | 1.28 (0.47–3.51) | 0.432   | 1.55 (0.52–4.60) |
| Micro stimulate   | 0.524            | 1.34 (0.54–3.31) | 0.449   | 0.65 (0.21–2.00) |
| Natural cycle    | 0.999            | –       | 1.000   | 0.001            | –       | 0       |
| No. of collected oocytes | 0.001          | 1.08 (1.03–1.12) | 0.987   | 1.00 (0.95–1.06) |
| No. of transferred embryos | 0.038          | 1.76 (1.03–1.12) | 0.014   | 2.04 (1.16–3.58) |
| Day 3/Day 5      | 0.145            | 0.49 (0.19–1.28) | 0.522   | 1.33 (0.55–3.19) |
| Constant         | 0.999            | 0.01    | 0.999   | 421.6            | –       | –       |

GH, growth hormone; BMI, body mass index; AMH, Anti-Mullerian hormone; AFC, Antral follicle count; OR, odd risk; CI, confidence interval; LDR, Long down-regulation.
TABLE 5 | Logistic regression for miscarriage, while adjusting for confounders.

| Maternal age < 35 years | Maternal age ≥ 35 years |
|-------------------------|-------------------------|
| **P-value**             | **OR 95%C.I**           | **P-value**             | **OR 95%C.I**           |
| GH                      | 0.108                   | 0.37 (0.11–1.24)        | 0.813                   | 0.91 (0.43–1.93)        |
| Maternal age            | 0.040                   | 0.86 (0.75–0.99)        | 0.000                   | 1.42 (1.22–1.66)        |
| Maternal BMI            | 0.600                   | 1.03 (0.92–1.16)        | 0.998                   | 1.00 (0.91–1.10)        |
| Infertility duration    | 0.581                   | 0.95 (0.80–1.13)        | 0.478                   | 0.97 (0.88–1.06)        |
| Primary infertility     | 0.360                   | 1.46 (0.85–3.32)        | 0.878                   | 1.06 (0.48–2.34)        |
| Nulliparous             | 0.647                   | 1.45 (0.30–7.12)        | 0.561                   | 0.74 (0.26–2.07)        |
| Main infertility cause  |                         |                         |                         |                         |
| Male                    | 0.461                   | 0.86 (0.75–0.99)        | 0.998                   | 1.42 (1.22–1.66)        |
| Female                  | 0.413                   | 1.80 (0.44–7.34)        | 0.998                   | 347498568.20 (0.00–)    |
| Mixed                   | 0.776                   | 0.79 (0.15–4.02)        | 0.998                   | 652989926.33 (0.00–)    |
| Unexplained             | 0.660                   | 1.58 (0.21–11.93)       | 0.998                   | 215804921.68 (0.00–)    |
| AMH                     | 0.687                   | 1.11 (0.86–1.80)        | 0.694                   | 1.11 (0.67–1.83)        |
| AFC                     | 0.225                   | 1.07 (0.96–1.20)        | 0.094                   | 0.89 (0.77–1.02)        |
| Protocol                |                         |                         |                         |                         |
| GnRH agonist long protocol | 0.427                   | 0.70 (0.23–2.06)        | 0.556                   | 1.50 (0.56–4.04)        |
| LDR                     | 0.512                   | 0.39 (0.15–1.00)        | 0.422                   | 1.50 (0.56–4.04)        |
| GnRH antagonist         | 0.051                   | 0.00 (0.00–)            | 0.333                   | 0.67 (0.29–1.52)        |
| Flare cycle             | 0.999                   | 0.00 (0.00–)            | 0.915                   | 1.09 (0.21–5.60)        |
| Micro stimulate         | 0.999                   | 0.00 (0.00–)            | 0.427                   | 0.40 (0.04–3.79)        |
| No. of collected oocytes| 0.001                   | 0.78 (0.67–0.90)        | 0.688                   | 0.98 (0.88–1.09)        |
| No. of transferred embryos | 0.091                   | 0.36 (0.11–1.18)        | 0.335                   | 0.59 (0.20–1.74)        |
| Day3/Day5               | 0.502                   | 1.79 (0.33–9.74)        | 0.851                   | 0.86 (0.17–4.40)        |
| Constant                | 1.000                   | 0.10                    | 0.994                   | 0.00                    |

GH, growth hormone; BMI, body mass index; AMH, Anti-Mullerian hormone; AFC, Antral follicle count; OR, odd risk; CI, confidence interval; LDR, Long down-regulation.

and different protocols; however, GH treatment significantly improved the day 3 embryo quality in young PORs who underwent LDR.

**Strengths and Limitations**
The strengths of this study were as follows. First, the patients included in this study fulfilled the POSEIDON criteria. POSEIDON was proposed to reduce the population heterogeneity of Bologna (29). Second, the sample size of this study was relatively large, while the duration of the study was only 18 months; thus, this study could reduce the bias of IVF/ICSI protocols at the same time. The study was mainly limited by the retrospective nature. GH supplementation may be selectively adopted to treat difficult PORs with a relatively low AFC and longer duration of infertility in the PG3 group (<35 years). In addition, this study did not include outcomes of cryopreserved embryos, thus the effectiveness of GH treatment in terms of a cumulative LBR may be underestimated (30).

**Interpretation of Data**
The rationale for add-on of GH to treat PORs was due to stimulation of IGF1, which has been reported to have synergistic effects with FSH on follicular development in an animal study (13). Moreover, GH treatment in older PORs increased the density of granulosa FSH and LH receptors (14). Two meta-analyses with few non-Bologna patients demonstrated statistically significant differences in CPR and LBR favoring the use of GH (24, 31). In contrast, a relatively large RCT, including 141 Bologna PORs, suggested that there was no statistically significant difference in CPR and LBR between the GH treatment and control groups (21). The other RCT conducted by LIGHT investigators, including 130 patients with at least one cycle of a poor response to COH, showed that the GH and control groups had a similar probability of achieving live births (32). Taken together, the discrepant findings may be related to different criteria employed for defining PORs (28). The heterogeneity of patients is associated with different underlying etiologies of PORs and may result in a variety of GH intervention effects. Based on clinical trials, there is no robust evidence to support widespread use of GH in treating PORs to date.

In this study, the distribution of AFC in the GH supplement group was skewed to an extremely low number (i.e., 0–1) in the PG3 group (<35 years). In addition, this study did not include outcomes of cryopreserved embryos, thus the effectiveness of GH treatment in terms of a cumulative LBR may be underestimated (30).
the day 3 embryo available rate were comparable in old PORs. In fact, the physician considered selecting young PORs to undergo GH treatment. The reduced total dose of gonadotrophins may be due to a higher proportion of patients undergoing the micro-stimulation protocol in the GH treatment group among PG4 patients. Nevertheless, these results did not favor GH usage in improving the CPR and LBR in expected PORs, the finding was in agreement with two recently published RCTs (21, 32). Moreover, recently a review suggested no benefit of increased LBR for PORs (33). Of note, there were significant differences in the COH protocol and number of oocytes collected. It has been reported that different stimulation protocols (agonist vs. antagonist) (34) and the number of oocytes collected (35, 36) may cause bias on the LBR. Hence, duration of infertility, the number of AFC, the number of oocytes collected, and COH protocol were adjusted in logistic regression along with other potential confounding factors. Finally, the results of logistic regression indicated that GH addition was not significantly associated with the LBR.

In previous studies, efficacy of GH treatment on CPR and LBR was investigated in PORs with different protocols; including antagonist (21, 23, 32), GnRH-a long protocol (22), mild stimulation protocol (37), the result was not consistent in these studies. Moreover, a prospective randomized trial suggested that the GnRH-a long protocol was superior to the other three protocols, such as GnRH-a short, mini-flare, and antagonist protocols, regarding the number of oocytes retrieved and fertilized, but the CPR difference was not statistically significant (38). Thus, it is necessary to break out PORs with different protocols. Consequently, PORs were further stratified based on the COH protocol to investigate which subgroup was optimal in terms of LBR, and while eliminating major bias in this study. The number of oocytes collected was not different between the two groups in the LDR and GnRH-a long protocols however, the day 3 embryo available rate was significantly increased after GH treatment in young PORs with LDR. Nevertheless, a similar CPR and LBR were observed in PORs with LDR and GnRH-a long protocols. Of note, the miscarriage rate was significantly reduced after GH usage in young PORs undergoing the antagonist protocol, but the LBR was still comparable between the GH treatment group, the number of oocytes collected was significantly lower in the GH treatment group; the number of available embryos between the two

### TABLE 6 | Clinical outcomes based on ovarian stimulation protocol.

|                      | Maternal age <35 | Maternal age ≥35 |
|----------------------|------------------|------------------|
|                      | GH               | CN               | P-value | GH               | CN               | P-value  |
| LDR                  |                  |                  |
| No. of oocytes collected | 8.41 ± 4.49      | 8.45 ± 4.71      | 0.969   | 8.45 ± 4.99      | 7.43 ± 5.38      | 0.287   |
| No. of cleavage oocytes | 122              | 845              |         | 243              | 592              |         |
| Day 3 embryo available rate | 77 (63.11%)    | 417 (49.35%)    | 0.004   | 109 (44.86%)     | 272 (45.95%)     | 0.774   |
| Cycles reaching ET     | 17               | 105              | 0.707   | 30               | 83               |         |
| Clinical pregnancy rate/ET (%) | 10 (58.82%)   | 44 (41.90%)      | 0.183   | 14 (48.28%)      | 31 (38.27%)      | 0.347   |
| Miscarriage rate/CP (%) | 0 (0%)           | 8 (14.29%)       | 0.023   | 2 (14.29%)       | 9 (29.03%)       | 0.458   |
| Live birth rate/ET (%) | 10 (58.82%)     | 44 (41.90%)      | 0.193   | 12 (43.33%)      | 21 (25.30%)      | 0.065   |
| GnRH agonist long protocol |                |                  |         |                  |
| No. of oocytes collected | 8.21 ± 5.18      | 9.08 ± 5.10      | 0.167   | 7.38 ± 4.66      | 6.87 ± 4.59      | 0.298   |
| No. of cleavage oocytes | 461              | 2.105            |         | 656              | 1.537            |         |
| Day 3 embryo available rate | 228 (49.46%)  | 1.134 (53.87%)   | 0.085   | 324 (49.39%)     | 788 (51.27%)     | 0.420   |
| Cycles reaching ET     | 60               | 246              |         | 86               | 217              |         |
| Clinical pregnancy rate/ET (%) | 25 (41.67%)   | 106 (43.09%)     | 0.842   | 20 (23.26%)      | 61 (28.11%)      | 0.389   |
| Miscarriage rate/CP (%) | 4 (16%)          | 13 (12.56%)      | 0.740   | 5 (25%)          | 14 (22.95%)      | 1.000   |
| Live birth rate/ET (%) | 20 (33.33%)     | 91 (36.99%)      | 0.597   | 15 (17.44%)      | 44 (20.28%)      | 0.574   |
| GnRH antagonist protocol |                |                  |         |                  |
| No. of oocytes collected | 5.92 ± 4.35      | 7.04 ± 4.83      | 0.019   | 5.07 ± 3.14      | 4.88 ± 4.10      | 0.478   |
| No. of cleavage oocytes | 539              | 2.303            |         | 1.017            | 2.246            |         |
| Day 3 embryo available rate | 288 (53.43%)  | 1.320 (57.32%)   | 0.101   | 538 (52.90%)     | 1.180 (52.54%)   | 0.848   |
| Cycles reaching ET     | 108              | 341              |         | 538              | 1180             |         |
| Clinical pregnancy rate/ET (%) | 39 (36.11%)   | 119 (34.90%)     | 0.818   | 40 (18.52%)      | 90 (20.04%)      | 0.642   |
| Miscarriage rate/CP (%) | 0 (0%)           | 15 (12.61%)      | 0.023   | 12 (30%)         | 18 (20%)         | 0.212   |
| Live birth rate/ET (%) | 38 (35.19%)     | 87 (28.45%)      | 0.183   | 28 (12.96%)      | 63 (14.03%)      | 0.707   |

GH, growth hormone; CN, control; ET, embryo transfer; CP, clinical pregnancy; LDR, Long down-regulation.
CONCLUSION

In conclusion, this study with expected PORs classified by the POSEIDON criteria demonstrated that growth hormone adjuvant therapy may not increase the probability of achieving a live birth in expected PORs whether single or double embryo transfer; however, a positive effect on embryo quality improvement was observed on sub-analysis.

STATEMENT

Poor ovarian responder (POR) was a therapeutic challenge in assisted reproduction treatment, mainly characterized by low ovarian reserve or poor response in previous ovarian stimulation. They were estimated to occur in 5.6–35.1% of patients, depending on the definition of POR. Growth hormone (GH) has been used for many years to increase the ovarian response in clinical practice. Previous literatures have found the benefit of GH usage with reduction in duration of ovarian stimulation, with a greater number of oocyte retrieved, and improvement in early clinical parameters. However, there is a lack of a clear definition of POR and participation heterogeneity in previous study. Until now, no benefit of GH usage with increased chance of live birth was determined. In this study, we set out to investigate the efficacy of GH adjuvant therapy in expected PORs based on POSEIDON classification. The results showed that growth hormone adjuvant therapy may not increase the probability of achieving live birth.

DATA AVAILABILITY STATEMENT

The datasets generated for this study are available on request to the corresponding author.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Ethics Committee of Reproductive Medicine, Peking University Third Hospital. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

AUTHOR CONTRIBUTIONS

JQ: conceived, designed the study, and revised the manuscript. PL and RL: coordinated data collection. JZ and YW: analyzed the data and drafted the manuscript. LC: statistical analysis.

FUNDING

This study was supported by the National Key Research & Development Program of China (2017YFC1001504) and the National Natural Science Foundation of China (81550022 and 81873833).

ACKNOWLEDGMENTS

This study was edited by International Science Editing.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fendo.2020.00001/full#supplementary-material

REFERENCES

1. Biljan MM, Buckett WM, Dean N, Phillips SJ, Tan SL. The outcome of IVF-embryo transfer treatment in patients who develop three follicles or less. Hum Reprod. (2000) 15:2140–4. doi: 10.1093/humrep/15.10.2140

2. De Sutter P, Dhont M. Poor response after hormonal stimulation for in vitro fertilization is not related to ovarian aging. Fertil Steril. (2003) 79:1294–8. doi:10.1016/S0015-0282(03)00264-4

3. Inge GB, Brinsden PR, Elder KT. Oocyte number per live birth in IVF: were steptoe and edwards less wasteful? Hum Reprod. (2005) 20:588–92. doi:10.1093/humrep/deh655

4. Veleza Z, Jarvela JY, Nuojua-Huttunen S, Martikainen H, Tapanainen JS. An initial low response predicts poor outcome in in vitro fertilization/intracytoplasmic sperm injection despite improved ovarian response in consecutive cycles. Fertil Steril. (2005) 83:1384–90. doi:10.1016/j.fertnstert.2004.11.056

5. Hendriks DJ, te Velde ER, Looman CW, Bancsi LF, Broekmans FJ. Expected poor ovarian response in predicting cumulative pregnancy rates: a powerful tool. Reprod Biomed Online. (2008) 17:727–36. doi:10.1684/s1472-6483(10)60323-9

6. Ornietto R, Meltzer S, Nahum R, Rabinson J, Antebiy EY, Ashkenazi J. The influence of body mass index on in vitro fertilization outcome. Int J Gynaecol Obstet. (2009) 104:53–5. doi:10.1016/j.ijigo.2008.08.012

7. Lainas TG, Sfondouris IA, Venetis CA, Lainas GT, Zorzovilis IZ, Tarlatzis BC, et al. Live birth rates after modified natural cycle compared with high-dose FSH stimulation using GnRH antagonists in poor responders. Hum Reprod. (2015) 30:2321–30. doi:10.1093/humrep/dev198

8. Drakopoulos PT, Vuong NL, Ho NAV, Vaiarelli A, Ho MT, Blockeel C, et al. Conifollitropin alfa followed by highly purified HMG versus recombinant FSH in young poor ovarian responders: a multicentre randomized controlled clinical trial. Hum Reprod. (2017) 32:2225–33. doi:10.1093/humrep/dex296

9. Mitri F, Behan LA, Murphy CA, Hershko-Klement A, Casper RF, Bentov Y. Microdose flare protocol with interrupted follicle stimulating hormone and added androgen for poor responders—an observational pilot study. Fertil Steril. (2016) 105:100–5 e1–6. doi:10.1016/j.fertnstert.2015.09.038

10. Balasch J, Fabregues F, Penarrubia J, Carmona F, Casamitjana R, Creus M, et al. Pretreatment with transdermal testosterone may improve

January 2020 | Volume 11 | Article 1

Zhu et al. Effect of GH on Improved LBR in PORs
ovarian response to gonadotrophins in poor-responder IVF patients with normal basal concentrations of FSH. Hum Reprod. (2006) 21:1884–93. doi: 10.1093/humrep/del052

11. Herraz S, Romeu M, Buigues A, Martinez S, Diaz-Garcia C, Gomez-Sequi I, et al. Autologous stem cell ovarian transplantation to increase reproductive potential in patients who are poor responders. Fertil Steril. (2018) 110:496–505 e1. doi: 10.1016/j.fertnstert.2018.04.025

12. Bachelot A, Mengut P, Imbert-Bollelo P, Coshigano K, Koppchick J, Kelly PA, et al. Growth hormone is required for ovarian follicular growth. Endocrinology. (2002) 143:4104–12. doi: 10.1210/en.2002-220087

13. Yoshimura Y, Iwashita M, Karube M, Oda T, Akiba M, Shiokawa S, et al. Growth hormone stimulates follicular development by stimulating ovarian production of insulin-like growth factor-I. Endocrinology. (1994) 135:887–94. doi: 10.1210/endo.135.3.8707383

14. S. Regan LP, Knight PG, Yovich JL, Arfsao F, Dharmarajan A. Growth hormone during in vitro fertilization in older women modulates the density of receptors in granulosa cells, with improved pregnancy outcomes. Fertil Steril. (2018) 110:1298–310. doi: 10.1016/j.fertnstert.2018.08.018

15. Weall BM, Al-Samerria S, Conceicao J, Yovich JL, Almahbobi G. A direct action for GH in improvement of oocyte quality in poor-responder patients. Reproduction. (2015) 149:147–54. doi: 10.1530/REP-14-0494

16. Homburg R, Eshel A, Abdalla HI, Jacobs HS. Growth hormone facilitates in vitro production of insulin-like growth factor-I. Endocrinology. (2002) 143:4104–12. doi: 10.1210/endo.2002-220087

17. Ibrahim ZH, Matson PL, Buck P, Lieberman BA. The use of biosynthetic human growth hormone to augment ovulation induction with buserelin acetate/human menopausal gonadotropin in women with a poor ovarian response. Fertil Steril. (1991) 55:202–4. doi: 10.1016/S0015-0282(16)54084-9

18. Dakhly DM, Bassiouny VA, Bayoumi YA, Hassan MA, Gouda HM, Hassan AA. The addition of growth hormone adjuvant therapy to the long down regulation protocol in poor responders undergoing in vitro fertilization: randomized controlled trial. Eur J Obstet Gynecol Reprod Biol. (2018) 228:161–5. doi: 10.1016/j.ejogrb.2018.06.035

19. Obđedoka K, Kogan I, Krikheldi I, Dhemilikhanova L, Muller V, Mekina I, et al. Growth hormone co-treatment in IVF/ICSI cycles in poor responders. Gynecol Endocrinol. (2017) 33:15–17. doi: 10.1080/09513590.2017.1399693

20. Choe SJ, Kim D, Lee HJ, Kim J, Chang EM, Kim JW, et al. Increased proportion of mature oocytes with sustained-release growth hormone treatment in poor responders: a prospective randomized controlled study. Arch Gynecol Obstet. (2018) 297:791–6. doi: 10.1007/s00404-017-4613-4

21. Bassiouny YA, Dakhly DM, Bayoumi YA, Hashish NM. Does the addition of growth hormone to the in vitro fertilization/intracytoplasmic sperm injection antagonist protocol improve outcomes in poor responders? A randomized, controlled trial. Fertil Steril. (2016) 105:697–702. doi: 10.1016/j.fertnstert.2015.11.026

22. Lattes K, Brasseco M, Gomeze M, Checa MA. Low-dose growth hormone supplementation increases clinical pregnancy rate in poor responders undergoing in vitro fertilization. Gynecol Endocrinol. (2015) 31:565–8. doi: 10.3109/09513590.2015.1025378

23. Eftekhar M, Afafotionan A, Mohammadian F, Eftekhar T. Adjuvant growth hormone therapy in antagonist protocol in poor responders undergoing assisted reproductive technology. Arch Gynecol Obstet. (2015) 287:1017–21. doi: 10.1007/s00404-012-2655-1

24. Kolibianakis EM, Venetis CA, Diedrich K, Tarlataz BS, Greissinger G. Addition of growth hormone to gonadotrophins in ovarian stimulation of poor responders treated by in vitro fertilization: a systematic review and meta-analysis. Hum Reprod Update. (2009) 15:613–22. doi: 10.1093/humupd/dmp026

25. Keane KN, Yovich JL, Hamidi A, Hinchliffe PM, Dhaliall WS. Single-centre retrospective analysis of growth hormone supplementation in IVF patients classified as poor-prognosis. BMJ Open. (2017) 7:e018107. doi: 10.1136/bmjopen-2017-018107

26. Cai MH, Liang YJ, Wu YQ, Huang R, Yang X. Six-week pretreatment with growth hormone improves clinical outcomes of poor ovarian responders undergoing in vitro fertilization treatment: a self-controlled clinical study. J Obstet Gynaecol Res. (2019) 45:376–81. doi: 10.1111/jog.13823

27. Hart RJ, Rombouts L, Norman RJ. Growth hormone in IVF cycles: any hope? Curr Opin Obstet Gynecol. (2017) 29:119–25. doi: 10.1097/GCO.0000000000000360

28. Polyzos NP, Devroey P. A systematic review of randomized trials for the treatment of poor ovarian responders: is there any light at the end of the tunnel? Fertil Steril. (2011) 96:1058–61 e7. doi: 10.1016/j.fertnstert.2011.09.048

29. Alviggi C, Andersen CY, Buehker K, Conforti A, De Placido G, Esteves SC, et al. A new more detailed stratification of low responders to ovarian stimulation: from a poor ovarian response to a low prognosis concept. Fertil Steril. (2016) 105:1452–3. doi: 10.1016/j.fertnstert.2016.02.005

30. Yovich JL, Ye Y, Keane KN. Growth hormone adjuvant trial for poor responders undergoing IVF. Eur J Obstet Gynecol Reprod Biol. (2019) 236:249. doi: 10.1016/j.ejogrb.2019.01.026

31. Dufy JM, Ahmad G, Mohiyddeen L, Nardo LG, Watson A. Growth hormone for in vitro fertilization. Cochrane Database Syst Rev. (2010) 1:CD000099. doi: 10.1002/14651858.CD000099.pub3

32. Norman RJ, Alvino H, Hull LM, Mol BW, Hart RJ, Kelly TL, et al. Human growth hormone for poor responders: a randomized placebo-controlled trial provides no evidence for improved live birth rate. Reprod Biomed Online. (2019) 38:908–15. doi: 10.1016/j.rbmo.2019.02.003

33. Hart RJ. Use of growth hormone in the IVF treatment of women with poor ovarian reserve. Front Endocrinol. (2019) 10:500. doi: 10.3389/endo.2019.00500

34. Sunkara SK, Coomarasamy A, Faris R, Braude P, Khalaf Y. Long gonadotropin-releasing hormone agonist versus short agonist versus antagonist regimens in poor responders undergoing in vitro fertilization: a randomized controlled trial. Fertil Steril. (2014) 101:147–53. doi: 10.1016/j.fertnstert.2013.09.035

35. Sunkara SK, Rittenberg V, Raine-Fenning N, Bhattacharya S, Zamora J, Coomarasamy A. Association between the number of eggs and live birth in IVF treatment: an analysis of 400 135 treatment cycles. Hum Reprod. (2011) 26:1768–74. doi: 10.1093/humrep/der106

36. De Geyter C, Fehr P, Moffat R, Gruber IM, von Wolff M. Twenty years experience with the swiss data registry for assisted reproductive medicine: outcomes, key trends and recommendations for improved practice. Swiss Med Wkly. (2015) 145:w14087. doi: 10.4414/smw.2015.14087

37. Chu K, Pang W, Sun N, Zhang Q, Li W. Outcomes of poor responders following growth hormone co-treatment with IVF/ICSI mild stimulation protocol: a retrospective cohort study. Arch Gynecol Obstet. (2018) 297:1317–21. doi: 10.1007/s00404-018-4725-5

38. Dakhly DM, Bayoumi YA, Gad Allah SH. Which is the best IVF/ICSI protocol to be used in poor responders receiving growth hormone as an adjuvant treatment? A prospective randomized trial. Gynecol Endocrinol. (2016) 32:116–9. doi: 10.3109/09513590.2015.1092136

39. Zhu J, Lian Y, Li M, Chen L, Liu P, Qiao J. Does IVF cleavage stage embryo quality affect pregnancy complications and neonatal outcomes in singleton gestations after double embryo transfers? J Assist Reprod Genet. (2014) 31:1635–41. doi: 10.1007/s10815-014-0351-8

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.